Cargando…

Immunological Features of Paranasal Sinus Mucosa in Patients with Graves’ Orbitopathy

BACKGROUND: Previous studies showed that patients with Graves’ orbitopathy (GO) had concomitant mucosal abnormality within the paranasal sinuses. It remains unknown whether the immunological reactions in sinus mucosa affect the orbit inflammation in GO. METHODS: Patients with GO underwent sinus comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yi, Wu, Yu, Huang, Yazhuo, Fang, Sijie, Li, Yinwei, Sun, Jing, Zhou, Huifang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902916/ https://www.ncbi.nlm.nih.gov/pubmed/33643223 http://dx.doi.org/10.3389/fendo.2020.621321

Ejemplares similares

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
por: Zhou, Huifang, et al.
Publicado: (2022)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2020)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Human Bocavirus DNA in Paranasal Sinus Mucosa
por: Falcone, Valeria, et al.
Publicado: (2011)

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
por: Villagelin, Danilo, et al.
Publicado: (2019)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Comparison of biological and mechanical properties of different paranasal sinus mucosa in goat
por: Fang, Xinyu, et al.
Publicado: (2022)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
por: Wagner, Lilly H., et al.
Publicado: (2022)

High IgG4 serum concentration is associated with active Graves orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2023)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses
por: Beule, Achim G.
Publicado: (2011)

Changes in paranasal sinus mucosa due to the nasopharyngian obstruction
por: Manole, Felicia
Publicado: (2013)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET
por: Ochmann, Anna, et al.
Publicado: (2023)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure
por: Fan, Shu-Xian, et al.
Publicado: (2021)

Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications
por: Urselli, Francesca, et al.
Publicado: (2019)

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
por: Oeverhaus, Michael, et al.
Publicado: (2023)

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study
por: Boutzios, Georgios, et al.
Publicado: (2023)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy—Preliminary Results From a Prospective Single-Center Study
por: Sarnat-Kucharczyk, Monika, et al.
Publicado: (2022)

Distinctive Features of Orbital Adipose Tissue (OAT) in Graves’ Orbitopathy
por: Zhang, Lei, et al.
Publicado: (2020)

The Effect of Lyso-PAF on Ciliary Activity of Human Paranasal Sinus Mucosa in vitro
por: Ganbo, T., et al.
Publicado: (1994)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i27v16nks32bj18dng4qnsce5r